Diabetes Patents (Class 514/866)
-
Patent number: 6551627Abstract: The invention is directed to a herbal medicinal composition for preventing or treating type II diabetes. The composition is comprised of extracts from Pterocarpus marsupium, Morus alba, Orthosiphon aristatus, Opiophogon japonicus, Rosa rugosa, Commelina communis, Trichosanthis kirilowii and Anemarrhena asphodeloides.Type: GrantFiled: May 3, 2001Date of Patent: April 22, 2003Assignee: Holomed Pharmaceuticals, Ltd.Inventors: Ji-Won Yoon, Hee-Sook Jun
-
Patent number: 6548049Abstract: This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing pioglitazone medicament and a fluid carrier.Type: GrantFiled: October 31, 2000Date of Patent: April 15, 2003Assignee: Aeropharm Technology IncorporatedInventors: Anthony J. Cutie, Akwete L. Adjei, Frederick A. Sexton
-
Patent number: 6544998Abstract: This invention relates to pharmaceutical compositions comprising combinations of a GABA agonist, a prodrug thereof or a pharmaceutically acceptable salt of said GABA agonist or said prodrug and a SDI, a prodrug thereof or a pharmaceutically acceptable salt of said SDI or said prodrug, kits containing such combinations and methods of using such combinations to treat mammals, including humans, suffering from diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic retinopathy, diabetic microangiopathy, diabetic macroangiopathy, cataracts or foot ulcers.Type: GrantFiled: November 29, 2001Date of Patent: April 8, 2003Assignee: Pfizer IncInventor: Banavara L. Mylari
-
Patent number: 6540983Abstract: This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a &bgr;-cell hypoglycemic agent and a fluid carrier.Type: GrantFiled: October 31, 2000Date of Patent: April 1, 2003Assignee: Aeropharm Technology IncorporatedInventors: Akwete L. Adjei, Anthony J. Cutie, John Z. Sun, Fred Sexton
-
Patent number: 6540982Abstract: This invention relates to a medicinal aerosol formulation and, more particularly, to a medicinal aerosol formulation an insulin combination and a fluid carrier.Type: GrantFiled: October 30, 2000Date of Patent: April 1, 2003Assignee: Aeropharm Technology IncorporatedInventors: Akwete L. Adjei, Anthony J. Cutie
-
Patent number: 6537806Abstract: The present invention provides an isolated population of cells containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsulin cleavage site to produce insulin. The invention also provides an isolated population of cells which further express a hexosamine synthetic pathway enzyme. The invention additionally provides vectors containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsulin cleavage site to produce insulin. The invention further provides a method of treating or preventing diabetes by implanting into an individual cells coexpressing proinsulin containing a proinsulin cleavage site and a glucose-regulated protease capable of cleaving the proinsulin cleavage site to produce insulin.Type: GrantFiled: November 4, 1998Date of Patent: March 25, 2003Assignee: University of WashingtonInventors: William R. A. Osborne, Nagarajan Ramesh
-
Patent number: 6534487Abstract: A method of suppressing appetite in a subject in need thereof comprises administering to said subject, in an effective appetite suppressing amount, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch. A method of enhancing exercise performance or recovery in a subject in need thereof comprises administering to said subject, in an amount effective to enhance exercise performance or recovery, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch.Type: GrantFiled: August 3, 1999Date of Patent: March 18, 2003Assignee: Childrens Hospital Los AngelesInventor: Francine R. Kaufman
-
Patent number: 6528502Abstract: A nutritional supplement for use in managing carbohydrates and enhancing anabolism in mammals is described. The nutritional supplement contains regulated amounts of niacin, chromium, and vanadium, and optionally thiamin, riboflavin, magnesium, and zinc. These vitamins and minerals mimic and/or enhance the physiological effects of insulin in the body. A method of using the composition is also described.Type: GrantFiled: August 8, 2000Date of Patent: March 4, 2003Assignee: Metagenics, Inc.Inventors: Kim Carleton Krumhar, Jeffrey J. Katke
-
Patent number: 6524618Abstract: An extended-release matrx formulation capable of being directly compressed into tablets comprising metformin hydrochloride blended with specific excipients. The excipients used in the formulation enhance the flow and compaction properties of the drug and insure that the formulation is directly compressible into a tablet containing about 100 mg to about 800 mg, preferably about 250 mg to about 750 mg, of metformin hydrochloride in unit dosage form. Each tablet produced by direct compression of the formulaton has the desired hardness and dissolution characteristics such that the drug is released in the body of the subject over an extended period of time.Type: GrantFiled: June 12, 2001Date of Patent: February 25, 2003Inventors: Vijai Kumar, Kevin Scott McGuffy
-
Patent number: 6525089Abstract: A pharmaceutical composition comprising decursin and its uses as a nephrotoxicity inhibitor, an antineoplastic agent, an antidiabetic agent, and as a cancer-cell differentiation induction agent are disclosed.Type: GrantFiled: April 19, 2001Date of Patent: February 25, 2003Assignee: Binex Co., Ltd.Inventors: Se Young Chong, Ik Hwan Kim, Kyung Seop Ahn, Sang Ki Kim
-
Patent number: 6518302Abstract: Compounds represented by general formula (I) wherein X represents OH or OSO3H; and R represents a substituent other than OH which allows, after leaving, the induction of unsaturated bonds into the 3- and 4-positions of 3,6-anhydrogalactose or its sulfated derivative, and/or a substituent showing a tissue-specific affinity.Type: GrantFiled: July 20, 2001Date of Patent: February 11, 2003Assignee: Takara Shuzo Co., Ltd.Inventors: Eiji Kobayashi, Tuo-Ping Li, Tatsuji Enoki, Takanari Tominaga, Hiroaki Sagawa, Ikunoshin Kato
-
Patent number: 6517870Abstract: An oral formulation comprising a biguanide and an organic acid has less unpleasant tastes such as bitterness and saltiness.Type: GrantFiled: October 27, 2000Date of Patent: February 11, 2003Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Hiroyuki Nishii, Hirohisa Kobayashi, Kazuya Otoda
-
Patent number: 6515117Abstract: An SGLT2 inhibiting compound is provided having the formula A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.Type: GrantFiled: May 20, 2002Date of Patent: February 4, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Bruce Ellsworth, William N. Washburn, Philip M. Sher, Gang Wu, Wei Meng
-
Patent number: 6511981Abstract: This invention is directed to methods, pharmaceutical compositions and kits comprising an aldose reductase inhibitor (ARI), a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug and a selective COX-2 inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or said prodrug. This invention further relates to methods of using those pharmaceutical compositions for the treatment of diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic retinopathy and diabetic cardiomyopathy.Type: GrantFiled: October 31, 2001Date of Patent: January 28, 2003Assignee: Pfizer IncInventor: Banavara L. Mylari
-
Patent number: 6506796Abstract: Methods of cosmetically or therapeutically treating diseases or disorders in cell populations whose pathology is linked to an inadequate rate of apoptosis by administering a therapeutically effective amount of 6-3-(1-adamantyl)-4-hydroxyphenyl)-2-naphthanoic acid.Type: GrantFiled: July 25, 2000Date of Patent: January 14, 2003Assignee: Centre International de Recherches Dermatologiques GaldermaInventors: Laszlo Fesus, Zsuzsa Szondy, Uwe Reichert
-
Patent number: 6506724Abstract: Methods for treating gestational diabetes which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood glucose levels.Type: GrantFiled: June 1, 1999Date of Patent: January 14, 2003Assignee: Amylin Pharmaceuticals, Inc.Inventors: Richard A. Hiles, Kathryn S. Prickett
-
Patent number: 6500804Abstract: The present invention discloses a method for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic &bgr;-cells and to cause differentiation of pancreatic epithelial cells into insulin producing &bgr;-cells. Oral administration a DP IV inhibitor causes the active form of GLP-1 to be preserved longer under physiological conditions. The extended presence of GLP-1, in particular in the pancreatic tissue facilitates differentiation and regeneration of the &bgr;-cells already present that are in need of repair. These repaired insulin producing cells can contribute to the correction and maintenance of normal physiological glycemic levels.Type: GrantFiled: April 2, 2001Date of Patent: December 31, 2002Assignee: Probiodrug AGInventors: Hans-Ulrich Demuth, Konrad Glund
-
Patent number: 6492337Abstract: The use of glycolipids, in particular galactosylceramide, glucosylceramide and lactosylceramide, and specific catchers therefor (antibodies or lectins), in particular monoclonal antibodies, for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications in an individual and for use in the production of pharmaceutical preparations for treatment of said conditions is disclosed.Type: GrantFiled: September 21, 2000Date of Patent: December 10, 2002Assignee: A+ Science ABInventors: Pam Fredman, Karsten Buschard
-
Patent number: 6492341Abstract: The present invention describes isolated Fagopyritol A1, isolated Fagopyritol A3, and isolated Fagopyritol B3. Compositions which include two or more of Fagopyritol A1, Fagopyritol A2, Fagopyritol A3, Fagopyritol B1, Fagopyritol B2, Fagopyritol B3, and D-chiro-inositol, at least one of which is an isolated Fagopyritol A1, isolated Fagopyritol A3, or isolated Fagopyritol B3, are also disclosed. Methods for preparing substantially pure Fagopyritol A1, Fagopyritol A3, Fagopyritol B3, or mixtures thereof from buckwheat are also described. The fagopyritols can be used to prepare pharmaceutical compositions, the administration of which can be used to treat diabetes.Type: GrantFiled: May 25, 2000Date of Patent: December 10, 2002Assignee: Cornell Research Foundation, Inc.Inventors: Ralph L. Obendorf, Marcin Horbowicz
-
Patent number: 6489331Abstract: A medicament for the therapeutic treatment of diabetes which comprises as an active ingredient a compound represented by the general formula (I): wherein R1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, R2 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, R3 represents a hydrogen atom, a lower alkyl group or a substituted or unsubstituted aralkyl group, X1 and X2 independently represent a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and the symbol “n” represents an integer of from 0 to 3, or a physiologically acceptable salt thereof.Type: GrantFiled: April 9, 2001Date of Patent: December 3, 2002Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Junichi Shimada, Yoshihisa Ohta, Kotaro Takasaki, Miho Suda, Hideaki Kusaka, Hiroshi Yano, Satoshi Nakanishi, Yuzuru Matsuda
-
Patent number: 6489345Abstract: Methods for treating diabetes mellitus and related conditions and symptoms are described. The methods are directed to administering a therapeutically effective amount of a compound. Compounds suitable for the invention include pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof. Also disclosed are methods directed to concurrently administering a therapeutically effective amount of a compound with other compounds known in the treatment of diabetes mellitus. In one embodiment, a therapeutically effective amount of a compound is administered concurrently with a therapeutically effective amount of insulin. In another embodiment, a therapeutically effective amount of a compound is administered concurrently with a therapeutically effective amount of a hypoglycemic compound.Type: GrantFiled: July 13, 2000Date of Patent: December 3, 2002Assignee: Medicure, Inc.Inventors: Rajat Sethi, Wasimul Haque
-
Patent number: 6479493Abstract: Substituted condensation products of -benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of type I diabetes.Type: GrantFiled: August 23, 2001Date of Patent: November 12, 2002Assignee: Cell Pathways, Inc.Inventors: Clark M. Whitehead, Keith A. Earle, Hector W. Alila, W. Joseph Thompson
-
Patent number: 6476071Abstract: A method whereby in an individual showing evidence of dysregulation of elements of the Polymorphic Metabolic Dysfunction (PMD), which is defined as the dysregulation of the metabolism of insulin, glucocorticoids, leptin, resistin and peroxisome proliferator-activated receptor &ggr; (PPAR&ggr;), this regulation is improved when that person receives an appropriate administration of (−)-hydroxycitric acid. The potassium salt of (−)-hydroxycitric acid is a preferred form of the compound, followed by the sodium salt, then by the amide and other salt forms and derivatives of the acid. The regulation of Polymorphic Metabolic Dysfunction over any given period of time may be improved with a controlled release form of (−)-hydroxycitric acid. Controlled release can be used to provide a sustained and modulated amount of the active to the body as desired and therefore to regulate the use of the compound as Polymorphic Metabolic Dysfunction regulative agent.Type: GrantFiled: May 7, 2001Date of Patent: November 5, 2002Inventors: Dallas L. Clouatre, James M. Dunn
-
Patent number: 6471963Abstract: Islet cell membrane antigen has been purified and, since it displaces islet cell surface antibodies, is of utility in the prevention or treatment of diabetes.Type: GrantFiled: May 30, 1995Date of Patent: October 29, 2002Assignee: KS Biomedix Ltd.Inventor: Kim Sze Tan
-
Patent number: 6468507Abstract: A non-aqueous medicinal aerosol formulation comprising rosiglitazone maleate, a fluid carrier, and an amino acid stabilizer. The aerosol formulation may also include drug combination formulations comprising rosiglitazone maleate and a second anti-diabetic medicament.Type: GrantFiled: October 31, 2000Date of Patent: October 22, 2002Assignee: Aeropharm Technology, Inc.Inventors: Anthony J. Cutie, Akwete L. Adjei, Frederick A. Sexton
-
Patent number: 6468537Abstract: The present invention includes peptides derived from nucleosomal histone proteins which are useful for delaying the onset and progression of systemic lupus erythematosus (i.e. lupus or SLE). The peptides of the invention span the histone proteins (i.e. H1, H2A, H2B, H3, and H4). The invention additionally encompasses isolated nucleic acids which encode these histone peptides as well as pharmaceutical compositions which comprise one or more of a histone peptide. Further, the invention provides kits which comprise one or more histone peptides or isolated nucleic acids encoding histone peptides and an instructional material. The invention also provides methods of using these compositions and analogs of histone peptides to inhibit an immune response and associated inflammation in an animal and to treat disorders in an animal which are related to the production of autoantibodies and complications thereof, such as inflammatory diseases, autoimmune disorders, and nephritis.Type: GrantFiled: April 28, 2000Date of Patent: October 22, 2002Assignee: The Board of Trustees of Northwestern UniversityInventors: Syamal K. Datta, Arunan Kaliyaperumal
-
Patent number: 6458782Abstract: Medicaments comprising a compound represented by the following formulas: wherein, R1 represents hydrogen atom or a C1-6 alkyl group; R2 and R3 represent hydrogen atom or a C1-6 alkyl group, or R2 and R3 may combine together with the carbon atoms of the phenyl ring to which R2 and R3 bind to represent a 5- or 6-membered ring; R4 represents hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxyl group etc.; R5 represents hydrogen atom, a C1-6 alkyl group, or an aryl-substituted C1-6 alkyl group; R6 represents hydrogen atom or a C1-6 alkyl group; X represents —NR7—, —NO—, —O— etc. in which R7 represents hydrogen atom, a C1-6 alkyl group etc.; and Y represents a phenylene group or a pyridinediyl group, which are useful for preventive and therapeutic treatments of diabetes and complications of diabetes.Type: GrantFiled: September 1, 2000Date of Patent: October 1, 2002Assignee: Institute of Medicinal Molecular Design, Inc.Inventors: Hiroyuki Kagechika, Yuichi Hashimoto, Hideji Fujii, Yoshiaki Yonekawa, Hisao Ekimoto
-
Patent number: 6458409Abstract: The dietetic food concentrate is a pourable powder containing soy protein, honey and at least 50% by weight of albumin so that it is easily digestible. It is made by mixing ⅓ to 6 percent by weight of lecithin with a protein-containing starting material to obtain an intermediate mixture, which is then mixed with 25 to 30 percent by weight of honey to obtain the product. The food concentrate powder contains 30 to 50 percent by weight soy isolate and an animal-protein-containing material, preferably a milk powder. During mixing in of the honey the temperature is preferably kept below 40° C. to avoid denaturing proteins. A method of treating a diabetic to reduce blood sugar level includes daily administration of an effective amount of the food concentrate powder. The product is also useful for reducing fat tissue and for treating amino acid deficiency illnesses.Type: GrantFiled: May 25, 2000Date of Patent: October 1, 2002Inventor: André Trouille
-
Patent number: 6455734Abstract: This invention provides a class of therapeutic compounds and methods for the treatment of mammals of physiological disorders, for example a frequently occurring type of essential hypertension, which are associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans,trans-1,3-butadienes, 1,3-perhydrobutadienes, 1,2-disubstituted trans ethylenes, and 1,2-disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.Type: GrantFiled: August 9, 2000Date of Patent: September 24, 2002Assignee: Magnesium Diagnostics, Inc.Inventor: Ibert Clifton Wells
-
Patent number: 6451836Abstract: The present invention relates to (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine and other substituted 2-methylpyrrolidines and their use for inhibiting liver glycogen phosphorylase.Type: GrantFiled: August 24, 1998Date of Patent: September 17, 2002Assignee: Novo Nordisk A/SInventors: Karsten Lundgren, Palle Jakobsen, Marit Kristiansen, Leif Nørskov-Lauritsen, Lars Naerum
-
Patent number: 6451342Abstract: This invention relates to a controlled release combination drug product comprising troglitazone, e.g. its hydrochloride, and a biguamide, e.g. metformin. In particular, the product comprises a core of metformin, at least a portion thereof has a layer or coat thereon of troglitazone.Type: GrantFiled: February 15, 2001Date of Patent: September 17, 2002Assignee: Aeropharm Technology IncorporatedInventors: Akwete L. Adjei, Yaping Zhu, Anthony J. Cutie
-
Patent number: 6451762Abstract: The present invention relates-to protracted acting, water-soluble aggregates of derivatives of human insulin, derivatives of human insulin capable of forming such aggregates, pharmaceutical compositions containing them, and to the use of such aggregates in the treatment of diabetes.Type: GrantFiled: January 8, 1999Date of Patent: September 17, 2002Assignee: Novo Nordisk A/SInventors: Svend Havelund, Ib Jonassen, Per Balschmidt, Thomas Høeg-Jensen
-
Patent number: 6444709Abstract: The invention relates to novel heteroethynylenic compounds having the general formula (I): as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.Type: GrantFiled: February 7, 2000Date of Patent: September 3, 2002Assignee: Galderma Research & Development S.N.C.Inventors: Philippe Diaz, Jean-Michel Bernardon
-
Patent number: 6440951Abstract: Fosfomycin or a pharmaceutically acceptable salt thereof has been found to have an action of lowering the serum glucose level and is recognized to be useful as an orally administrable remedy for treating diabetes. It has further been found that the serum glucose level-lowering action of fosfomycin or its salt can be enhanced synergistically and significantly when forfomycin is administered in association with vanadyl sulfate and the like. Therefore,the composition comprising fosfomycin or its salt and vanadyl sulfate or the like is useful as an orally administrable remedy for treating diabetes.Type: GrantFiled: November 26, 2001Date of Patent: August 27, 2002Assignee: Meiji Seika Kaisha, Ltd.Inventors: Tetsutaro Niizato, Masaharu Shiotani, Yoko Shoji
-
Patent number: 6432383Abstract: A mixed micellar pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal lauryl sulphate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compounds. The absorption enhancing compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof. The amount of each absorption enhancing compound is present in a concentration of from 1 to 10 wt./wt. % of the total formulation, and the total concentration of absorption enhancing compounds are less than 50 wt./wt. % of the formulation. A method for administering insulin to the buccal mucosa using a metered dose inhaler is also disclosed.Type: GrantFiled: March 30, 2000Date of Patent: August 13, 2002Assignee: Generex Pharmaceuticals IncorporatedInventor: Pankaj Modi
-
Patent number: 6428825Abstract: The present invention relates to an herbal therapeutic product for controlling diabetes mellitus comprising at least one hypoglycemic compound extracted from the pulp of fruit Eugenia jambolana. The process for the preparation of the herbal therapeutic product to control the glucose level, comprises cleaning and drying the fruit of a species of family Eugenia to remove extraneous material from the outermost layer of the said fruit. De-seeding the fruit and soaking the said de-seeded fruit in water under controlled cooled conditions overnight to retain the activity of hypoglycemic compounds in the mixture of water and pulp of de-seeded fruit. It is followed by mixing the mixture to achieve a uniform consistency.Type: GrantFiled: February 5, 2001Date of Patent: August 6, 2002Assignee: Indian Council of Medical ResearchInventors: Suman Bala Sharma, Pothapragada Suryanarayana Murthy, Krishan Madhav Prabhu, Afreena Nasir
-
Patent number: 6426341Abstract: This invention is directed to methods, pharmaceutical compositions and kits comprising an aldose reductase inhibitor (ARI), a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug and a selective COX-2 inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or said prodrug. This invention further relates to methods of using those pharmaceutical compositions for the treatment of diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, myocardial infarction, cataracts and diabetic cardiomyopathy.Type: GrantFiled: June 23, 2000Date of Patent: July 30, 2002Assignee: Pfizer Inc.Inventor: Banavara L. Mylari
-
Patent number: 6416765Abstract: The invention encompasses a method for treating hyperinsulinemic type 2 diabetes by local administration of a neurotoxin, such as a botulinum toxin, into the pancreas, thereby reducing insulin secretion from a B cell, and a method for treating hypoinsulinemic type 2 diabetes by local administration of a neurotoxin, such as a botulinum toxin, into a sympathetic ganglion, thereby reducing an inhibitory effect upon insulin secretion.Type: GrantFiled: October 3, 2001Date of Patent: July 9, 2002Assignee: Allergan Sales, Inc.Inventor: Stephen Donovan
-
Patent number: 6417164Abstract: Methods for treating non-insulin-taking Type II diabetes mellitus which comprise administering a therapeutically effective amount of an amylin agonist.Type: GrantFiled: November 6, 2000Date of Patent: July 9, 2002Assignee: Amylin Pharmaceuticals, Inc.Inventors: Orville G. Kolterman, Robert G. Thompson, John F. Mullane
-
Patent number: 6417208Abstract: The present invention provides a method of identifying novel agents that increase glucose dependent insulin secretion in pancreatic islet cells as well as methods of treating diabetes using the agents which have an inhibitory effect on the activity of pancreatic islet cell phosphodiesterases (“PDE”) enzyme, namely PDE1C. The methods described herein are based upon the inventor's surprising discovery that inhibition of PDE1C increases glucose dependent insulin secretion. Specifically, the present invention provides for a method of identifying therapeutic agents that act to increase the release of insulin from pancreatic islet cells. The method of identification provided herein is used to determine the effects of isozyme specific phosphodiesterase inhibitors on insulin secretion from cultured pancreatic &bgr;-cells. Also provided are agents that have an inhibitory effect on the activity of PDE1C in pancreatic cells.Type: GrantFiled: February 5, 1999Date of Patent: July 9, 2002Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventor: Tamar H. Michaeli
-
Patent number: 6417237Abstract: Macromolecular drug complexes containing a drug, like human growth hormone, and a polymer having a plurality of acid moieties, like carboxyl moieties or phosphonic acid moieties, and compositions containing the same, are disclosed. Compositions, particularly microemulsions, containing the macromolecular complexes are administered to individuals suffering from a disease or condition, and the complexes release the drug, in vivo, to treat the disease or condition, and to reduce, eliminate, or reverse complications associated with the disease.Type: GrantFiled: June 8, 2000Date of Patent: July 9, 2002Assignee: The Board of Trustees of the University of IllinoisInventors: Eric J. Dadey, Camillia Zamiri
-
Patent number: 6413965Abstract: This invention is directed to methods, pharmaceutical compositions and kits comprising an aldose reductase inhibitor (ARI), a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug and a selective COX-2 inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or said prodrug. This invention further relates to methods of using those pharmaceutical compositions for the treatment of diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic retinopathy and diabetic cardiomyopathy.Type: GrantFiled: June 23, 2000Date of Patent: July 2, 2002Assignee: Pfizer Inc.Inventor: Banavara L. Mylari
-
Patent number: 6414012Abstract: Heterocyclic derivatives of the formula (I) wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and method of producing them. Pharmaceutical compositions containing the heterocyclic derivative or a pharmaceutically acceptable salt thereof, particularly, ACAT inhibitors and lipoperoxidation inhibitors. The heterocyclic derivatives and pharmaceutically acceptable salts thereof of the present invention show superior ACAT inhibitory activity and lipoperoxidation inhibitory activity, and are useful as ACAT inhibitors and hyperlipemia inhibitors. To be specific, they are useful for the prevention and treatment of arteriosclerotic lesions of arteriosclerosis, hyperlipemia and diabetes, as well as ischemic diseases of brain, heart and the like.Type: GrantFiled: August 12, 1999Date of Patent: July 2, 2002Assignee: Sankyo Company, LimitedInventors: Hiroshi Matsui, Shoji Kamiya, Hiroaki Shirahase, Shohei Nakamura, Katsuo Wada
-
Patent number: 6413976Abstract: Compositions containing propentofylline, and methods for treating neuropathic pain with such compositions, are disclosed.Type: GrantFiled: February 4, 2002Date of Patent: July 2, 2002Assignee: Trustees of Dartmouth CollegeInventors: Joyce A. DeLeo, Peter Schubert
-
Patent number: 6413946Abstract: Fosfomycin or a pharmaceutically acceptable salt thereof has been found to have an action of lowering the serum glucose level and is recognized to be useful as an orally administrable remedy for treating diabetes. It has further been found that the serum glucose level-lowering action of fosfomycin or its salt can be enhanced synergistically and significantly when fosfomycin is administered in association with vanadyl sulfate and the like. Therefore, the composition comprising fosfomycin or its salt and vanadyl sulfate or the like is useful as an orally administrable remedy for treating diabetes.Type: GrantFiled: March 31, 2000Date of Patent: July 2, 2002Assignee: Meiji Seika Kaisha, Ltd.Inventors: Tetsutaro Niizato, Masaharu Shiotani, Yoko Shoji
-
Patent number: 6414126Abstract: SGLT2 inhibiting compounds are provided having the formula where R1, R2, and R2a are independently hydrogen, OH, OR5, lower alkyl, CF3, OCHF2, OCF3, SR5i or halogen, or two of R1, R2 and R2a together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle; R3 and R4 are independently hydrogen, OH, OR5a, OAryl, OCH2Aryl, lower alkyl, cycloalkyl, CF3, —OCHF2, —OCF3, halogen, —CN, —CO2R5b, —CO2H, —COR6b, —CH(OH)R6c, —CH(OR5h)R6d, —CONR6R6a, —NHCOR5c, —NHSO2R5d, —NHSO2Aryl, Aryl, —SR5e, —SOR5f, —SO2R5g, —SO2Aryl, or a five, six or seven membered heterocycle, or R3 and R4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle; R5, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h and R5i are independently lower alkyl; R6, R6a, R6b, R6c and R6d are independently hydrogen, alkyl,Type: GrantFiled: October 4, 2000Date of Patent: July 2, 2002Assignee: Bristol-Myers Squibb CompanyInventors: Bruce Ellsworth, William N. Washburn, Philip M. Sher, Gang Wu, Wei Meng
-
Patent number: 6410511Abstract: The present invention is concerned with a pharmaceutical formulation in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen, comprising approximately 0.01 to about 0.5% (w/v) amylin agonist, preferably pramlintide, in an aqueous system along with approximately 0.02 to about 0.5% (w/v) of an acetate, phosphate, citrate, or glutamate buffer to a pH of the final composition of approximately 3.0 to about 6.0 as well as approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol tonicifier; and, optionally, approximately 0.005 to 1.0% (w/v) of a preservative selected from the group consisting of m-cresol, benzyl alcohol, parabens and phenol. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin in the same syringe for administration to a patient.Type: GrantFiled: January 9, 1998Date of Patent: June 25, 2002Assignee: Amylin Pharmaceuticals, Inc.Inventors: James L'Italien, Shankar Musunuri, Kale Ruby
-
Patent number: 6410513Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.Type: GrantFiled: May 18, 2000Date of Patent: June 25, 2002Assignee: Eli Lilly and CompanyInventors: John A. Galloway, James A. Hoffman
-
Patent number: 6399090Abstract: An infant formula in a powder or solution form including nutritional components and an insulin supplement. A method of feeding an infant including the steps of dissolving an infant formula powder containing nutritional components and an insulin supplement in water for obtaining a solution including said nutritional components and said insulin supplement and feeding the infant with the solution.Type: GrantFiled: December 17, 2001Date of Patent: June 4, 2002Assignee: Insotech Ltd.Inventor: Naim Shehadeh
-
Patent number: 6395779Abstract: A method of therapeutically treating wounds, circulatory insufficiencies and skin disorders, in diabetics, is provided. The method involves the therapeutic application of peroxidized lipids or compositions containing peroxidized lipids to an area of skin of a subject with a diabetic condition including a wound, a skin disorder, or with insufficient circulation. The method is effective for promoting the healing of wounds, in particular, in patients having circulatory insufficiencies and/or diabetes.Type: GrantFiled: January 28, 2000Date of Patent: May 28, 2002Assignees: Neoteric Cosmetics, Inc., Laboratoires Carilene S.A.Inventors: Eileen P. Koop, Mary Jo Schwarz, Stephan Desjonqueres